Literature DB >> 32043760

Standardized flattening filter free volumetric modulated arc therapy plans based on anteroposterior width for total body irradiation.

Rebecca Frederick1,2, Alana Hudson1,3, Alex Balogh3,4, Jeffrey Q Cao3,4, Greg Pierce1,2,3.   

Abstract

In this work, the feasibility of using flattening filter free (FFF) beams in volumetric modulated arc therapy (VMAT) total body irradiation (TBI) treatment planning to decrease protracted beam-on times for these treatments was investigated. In addition, a methodology was developed to generate standardized VMAT TBI treatment plans based on patient physical dimensions to eliminate plan optimization time. A planning study cohort of 47 TBI patients previously treated with optimized VMAT ARC 6 MV beams was retrospectively examined. These patients were sorted into six categories depending on height and anteroposterior (AP) width at the umbilicus. Using Varian Eclipse, clinical 40 cm × 10 cm open field arcs were substituted with 6 MV FFF. Mid-plane lateral dose profiles in conjunction with relative arc output factors (RAOF) yielded how far a given multileaf collimator (MLC) leaf must move in order to achieve a mid-plane 100% isodose for a specific control point. Linear interpolation gave the dynamic MLC aperture for the entire arc for each patient AP width category, which was subsequently applied through Python scripting. All FFF VMAT TBI plans were then evaluated by two radiation oncologists and deemed clinically acceptable. The FFF and clinical VMAT TBI plans had similar Body-5 mm D98% distributions, but overall the FFF plans had statistically significantly increased or broader Body-5 mm D2% and mean lung dose distributions. These differences are not considered clinically significant. Median beam-on times for the FFF and clinical VMAT TBI plans were 11.07 and 18.06 min, respectively, and planning time for the FFF VMAT TBI plans was reduced by 34.1 min. In conclusion, use of FFF beams in VMAT TBI treatment planning resulted in dose homogeneity similar to our current VMAT TBI technique. Clinical dosimetric criteria were achieved for a majority of patients while planning and calculated beam-on times were reduced, offering the possibility of improved patient experience.
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Entities:  

Keywords:  flattening filter free; total body irradiation; treatment planning; treatment technique comparison; volumetric modulated arc therapy

Mesh:

Year:  2020        PMID: 32043760      PMCID: PMC7075390          DOI: 10.1002/acm2.12827

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


  21 in total

1.  Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients.

Authors:  M Ozsahin; F Pène; E Touboul; B Gindrey-Vie; C Dominique; D Lefkopoulos; C Krzisch; J Balosso; L Vitu; L H Schwartz
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

2.  Long-term complications of total body irradiation in adults.

Authors:  O Thomas; M Mahé; L Campion; S Bourdin; N Milpied; G Brunet; A Lisbona; A Le Mevel; P Moreau; J Harousseau; J Cuillière
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-01-01       Impact factor: 7.038

3.  Idiopathic interstitial pneumonia following bone marrow transplantation: the relationship with total body irradiation.

Authors:  T J Keane; J Van Dyk; W D Rider
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-10       Impact factor: 7.038

4.  Current practice in total-body irradiation: results of a Canada-wide survey.

Authors:  R C N Studinski; D J Fraser; R S Samant; M S MacPherson
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

5.  Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis.

Authors:  Natsuo Oya; Keisuke Sasai; Seiji Tachiiri; Takashi Sakamoto; Yasushi Nagata; Takashi Okada; Shinsuke Yano; Takayuki Ishikawa; Takashi Uchiyama; Masahiro Hiraoka
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

6.  The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Authors:  James A Russell; William Irish; Alexander Balogh; M Ahsan Chaudhry; Mary Lynn Savoie; A Robert Turner; Loree Larratt; Jan Storek; Nizar J Bahlis; Christopher B Brown; Diana Quinlan; Michelle Geddes; Nancy Zacarias; Andrew Daly; Peter Duggan; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-03       Impact factor: 5.742

7.  Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.

Authors:  Takahiro Fukuda; Robert C Hackman; Katherine A Guthrie; Brenda M Sandmaier; Michael Boeckh; Michael B Maris; David G Maloney; H Joachim Deeg; Paul J Martin; Rainer F Storb; David K Madtes
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

8.  Interstitial pneumonitis following autologous bone-marrow transplantation conditioned with cyclophosphamide and total-body irradiation.

Authors:  M Ozsahin; Y Belkacémi; F Pène; J Laporte; B Rio; V Leblond; D Korbas; E Touboul; N C Gorin; M Schlienger; A Laugier
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-01-01       Impact factor: 7.038

9.  Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation.

Authors:  Dong-Yun Kim; Il Han Kim; Sung-Soo Yoon; Hyoung Jin Kang; Hee Young Shin; Hyun-Cheol Kang
Journal:  Radiat Oncol       Date:  2018-09-18       Impact factor: 3.481

10.  Extended SSD VMAT treatment for total body irradiation.

Authors:  Greg Pierce; Alex Balogh; Rebecca Frederick; Deborah Gordon; Adam Yarschenko; Alana Hudson
Journal:  J Appl Clin Med Phys       Date:  2018-12-27       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.